Safety of C1-Inhibitor for Clinical Use
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Horstick and colleagues1 recently reported detrimental side effects of C1-inhibitor (C1inh) in pigs with myocardial ischemia. Local complement activation contributes to ischemic myocardium injury, and complement inhibition constitutes a novel therapeutic approach for coronary syndromes. C1inh reduces reperfusion injury in various animal models of myocardial infarction (MI). In dogs, we found that C1inh also reduced myocardial injury after permanent coronary occlusion2 and did not reduce tensile strength of the scar area. C1inh prepared from human plasma has been given safely for 30 years to patients with angio-edema. We …